• CG Oncology reported cretostimogene achieved a 41.8% complete response rate at 24 months in Phase 3 BOND-003 Cohort C.
• The cohort’s complete response rate reached 75.5% at any time; 46.4% at 12 months.
• No grade 3 or higher treatment-related adverse events were reported for cretostimogene.
• BOND-003 Cohort P showed 80.4% high-grade event-free survival at nine months in patients with BCG-unresponsive papillary-only bladder cancer.
• Manufacturing capacity stands at 40,000–50,000 vials annually, with a tenfold scale-up underway to support future indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.